National Institute on Alcohol Abuse and Alcoholism (NIAAA)

118 total trials 99 currently recruiting 19 completed

Trial Pipeline

RECRUITING Phase 1

Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors

NCT06819189

RECRUITING Phase 4

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627

RECRUITING Phase 1

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075

RECRUITING

Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)

NCT05677321

RECRUITING

Mechanisms Underlying Individual Variations of Taste and Smell in Obesity

NCT04714892

RECRUITING Phase 1

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

NCT04781322

RECRUITING

COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study

NCT04391816

RECRUITING Phase 1

Nicotinic Receptor Genetic Variation and Alcohol Reward

NCT03294460

RECRUITING Phase 2

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

NCT03407079

RECRUITING NA

Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

NCT02535702

RECRUITING

NIAAA Natural History Protocol

NCT02231840

RECRUITING

Characterization Imaging Instruments in Alcoholics and Non-Alcoholics

NCT02108080

RECRUITING NA

Behavioral and Functional Task Development, Implementation, and Testing

NCT02108054

COMPLETED Phase 1

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

NCT03326245

COMPLETED Phase 1

Human Laboratory Study of Varenicline for Alcohol Use Disorder

NCT03035708

COMPLETED Phase 2

HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder

NCT02252536

COMPLETED Early Phase 1

Brain Inflammation and Function in Alcoholism

NCT02233868

COMPLETED

Neural Substrates of Approach-Avoidance Conflict

NCT02119624

COMPLETED Phase 1

A Novel Compound for Alcoholism Treatment

NCT02039349

COMPLETED Phase 2

Baclofen for Treating Anxiety and Alcoholism

NCT01751386

COMPLETED Phase 1

Computer-Assisted Self-Administration of Ethanol

NCT00713492

COMPLETED Early Phase 1

The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion

NCT00667771

COMPLETED Phase 2

Aripiprazole and Topiramate on Free-Choice Alcohol Use

NCT00884884

COMPLETED Phase 2

Effect of LY686017 on Alcohol Craving

NCT00310427

COMPLETED

Influence of Age and Sex on Alcohol Metabolism and Acute Responses

NCT00070577

COMPLETED Phase 2

Hangover, Congeners, Sleep and Occupational Performance

NCT00247585

COMPLETED Phase 2

A Placebo-Controlled Trial of Memantine for Alcohol Dependence

NCT00246415

COMPLETED Phase 2

Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

NCT00027079

COMPLETED Phase 1

Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress

NCT00014027

COMPLETED Phase 4

Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)

NCT00006204

COMPLETED

The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics

NCT00001675

COMPLETED Phase 2

Ondansetron Treatment for Alcoholism

NCT00000443

What the Pipeline for National Institute on Alcohol Abuse and Alcoholism (NIAAA) Shows

According to the ClinicalTrials.gov registry, National Institute on Alcohol Abuse and Alcoholism (NIAAA) is linked to 118 US clinical trials across every stage of research activity. Of those, 99 studies are currently recruiting — about 84% of the sponsor's indexed portfolio — and 19 are already marked complete, representing roughly 16% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for National Institute on Alcohol Abuse and Alcoholism (NIAAA) reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 75 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for National Institute on Alcohol Abuse and Alcoholism (NIAAA) is Alcoholism with 11 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial